Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-FLT3 CAR-T cells HG-CT-1

A preparation of autologous T lymphocytes genetically modified with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-FLT3 CAR-T cells HG-CT-1 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-FLT3 CAR T cells HG-CT-1
HEMO-CAR-T
Code name:HG-CT 1
HG-CT-1
HG-CT1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search